A PYMNTS Company

EU Antitrust Regulators Extend Illumina, Grail Deadline To March 4

By  |  January 25, 2022

EU antitrust regulators have extended the deadline for their decision on US life sciences company Illumina’s bid for $8 billion cash-and-stock takeover of Grail to March 4, according to a European Commission filing.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The five working day extension followed a 15 working day extension last month.

    The deal, unveiled in September 2020, would give Illumina access to Grail’s flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat.

    The EU competition watchdog has previously cautioned that the acquisition could curb innovation and competition.

    Illumina however has rejected such concerns, saying that Menlo Park, California-based Grail has no presence in Europe and has no plans to enter the region for the foreseeable future.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.